Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 November 2006, Vol. 108, No. 9, pp. 3195-3203.
Prepublished online as a Blood First Edition Paper on July 11, 2006; DOI 10.1182/blood-2006-05-020867.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-05-020867v1
108/9/3195    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glickstein, H.
Right arrow Articles by Cabantchik, Z I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glickstein, H.
Right arrow Articles by Cabantchik, Z I
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted May 1, 2006
Accepted June 21, 2006

Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences

Hava Glickstein, Rinat Ben El, Gabi Link, William Breuer, Abraham M Konijn, Chaim Hershko, Hanspeter Nick, and Z I Cabantchik*

Dept of Biological Chemistry & Charles E. Smith Lab. of Psychobiology, Hebrew University, Jerusalem
Department of Human Nutrition & Metabolism, Faculty of Medicine, Hebrew University, Jerusalem
Department of Hematology, Shaa're Zedek Medical Center, Jerusalem, Israel
Novartis Institutes for BioMedical Research, Basel, Switzerland

* Corresponding author; email: ioav{at}cc.huji.ac.il.

Labile iron in hemosiderotic plasma and tissue are sources of iron toxicity. We compared the iron chelators deferoxamine, deferiprone and deferasirox as scavengers of labile iron in plasma and cardiomyocytes at therapeutic concentrations. This comprised: chelation of labile plasma iron (LPI) in samples from thalassemia patients; extraction of total cellular iron; accessing labile iron accumulated in organelles and preventing formation of reactive-oxidant species and restoring impaired cardiac contractility. Neonatal rat cardiomyocytes were used for: a. monitoring chelator extraction of LCI (Labile Cell Iron) as 59Fe; b. assessing in situ cell iron chelation by epifluorescence microscope imaging using novel fluorescent sensors for iron and ROS selectively targeted to organelles and c. monitoring contractility by time-lapse microscopy. At plasma concentrations attained therapeutically, all three chelators eliminated LPI but the orally active chelators rapidly gained access to the LCI pools of cardiomyocytes, bound labile iron, attenuated ROS formation, extracted accumulated iron and restored contractility impaired by iron overload. The effect of deferoxamine at therapeutically relevant concentrations was primarily by elimination of LPI. The rapid accessibility of the oral chelators deferasirox and deferiprone to intracellular labile iron compartments renders them potentially efficacious for protection from and possibly reversal of cardiac damage induced by iron-overload.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020